In the third study, SURPASS-3, researchers evaluated the efficacy and safety of tirzepatide compared to titrated insulin degludec in people with T2DM who had inadequate control of metformin with or without SGLT2 inhibitors. This evidence concerns the gene INS and type 2 diabetes mellitus.